TY - JOUR T1 - Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503) JF - Anticancer Research JO - Anticancer Res SP - 2027 LP - 2031 VL - 28 IS - 4B AU - DIETMAR W. SIEMANN AU - WENYIN SHI Y1 - 2008/07/01 UR - http://ar.iiarjournals.org/content/28/4B/2027.abstract N2 - Background: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents. Materials and Methods: Human clear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay. Results: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503. Conclusion: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -